Sanofi Shares Hit Their Highest Level in 150 Sessions at €82.03
The pharmaceutical company extends its October rebound on a CAC 40 that is clearly higher. The stock has just passed a level watched for several weeks, a few days after the group raised its targets.
The 150-Session High Is Broken, Supported by Much Lower Moving Averages
Trading at €82.42 intraday, Sanofi gains 1.78% and moves above €82.03, its highest level of the last 150 sessions, which now acts as support.
The stock had already moved back above €80.98 earlier, the highest level of the last 30 sessions. This advance is visible in the gap to the moving averages: the price is 7.5% above the MM200 (€76.66) and nearly 11% above the MM50 (€74.28).
The RSI at 78 signals an overbought configuration. Over the week, the stock gains 9.67%, and 16.4% over one month, but it still falls 5.2% over one year. The CAC 40 rises 1.52% at the same time, and Sanofi ranks mid-table within the index.
Third-Quarter Revenue Up 14.3% and a Raised 2026 Outlook Behind the Rebound
On October 30, the group raised its 2026 targets after quarterly revenue rose 14.3% at constant exchange rates and earnings per share from business activities increased 19.6%, driven by Dupixent.
The stock was then trading around €79.70 and broke above its €79.74 resistance for the first time on November 2. Based on the consensus of the analysts covered, the share trades at about 9.6 times current-year earnings. The next identified resistance lies at €90.44, about 9.7% above the current price.
